23
2373.HK
—
HKEX
Personal Services
Beauty Farm Medical & Health Industry Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
2,67 %
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About
Beauty Farm Medical & Health Industry Inc provides personal and household products and services, focusing on the personal services segment.
Business. Beauty Farm Medical & Health Industry Inc (2373.HK) is a personal services company operating within the Consumer Non-Cyclicals sector. The firm is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not provided in the available data. Consequently, the company is described at the industry level as a provider of personal services.
Classification92 %
SectorConsumer Non-Cyclicals
Business sectorPersonal & Household Products & Services
IndustryPersonal Services
Generated · model-assisted
Sell-side consensus
BUY7 analysts
7 buy0 hold0 sell
Avg 12m price target35,29
Analyst recommendations
7 analysts · consensus BuyBuy7
Hold0
Sell0
12-month price target
35,29
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
7 analysts · indicative
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to 2373.HK. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Beauty Farm Medical & Health Industry Inc (2373.HK) is a personal services company operating within the Consumer Non-Cyclicals sector. The firm is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not provided in the available data. Consequently, the company is described at the industry level as a provider of personal services.
Classification92 %
SectorConsumer Non-Cyclicals
Business sectorPersonal & Household Products & Services
IndustryPersonal Services
AI synthesis
GENERATED— missing data
Key takeaways
- Beauty Farm Medical & Health Industry Inc has no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities.
- Analysts have issued a generally positive outlook, with a mean price target of 35.29 CNY and a median price target of 37.36 CNY.
- Liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
- No profitability or returns data is available for comparison to industry_config preferred metrics or cohort medians.
- The company's segments and geographic exposure are not disclosed, making it impossible to assess revenue concentration or geographic diversification.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Annual
ANNUALFiled 2026-03-27
FY 2026 · Full-year highlights
Revenue ¥3.00B, +16,6% YoY; Operating income +42,8% YoY.
Revenue¥3.00B+16,6 % YoY
Operating income¥459.5M+42,8 % YoY
Net income¥317.6M+39,0 % YoY
Free cash flow¥552.3M+36,4 % YoY
EPS—
Operating cash flow¥999.1M+25,4 % YoY
Financials
Income statement
Revenue¥3.00B
Gross profit¥1.47B
Operating income¥459.5M
Net income¥317.6M
Margins
Gross margin49.1%
Operating margin15.3%
Net margin10.6%
FCF margin18.4%
Balance sheet
Total assets¥5.05B
Total liabilities¥4.02B
Total equity¥1.02B
Cash & equivalents¥1.63B
Long-term debt¥1.29B
Cash flow
Operating cash flow¥999.1M
CapEx-¥67.1M
Free cash flow¥552.3M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue ¥3.00B, +16,6% YoY
- ▍Operating income +42,8% YoY
- ▍Net income +39,0% YoY
- ▍Free cash flow +36,4% YoY
- ▍Net margin 10.6%
ANNUALFiled 2025-03-26
FY 2025 · Full-year highlights
Revenue ¥2.57B, +19,9% YoY; Operating income +10,5% YoY.
Revenue¥2.57B+19,9 % YoY
Operating income¥321.8M+10,5 % YoY
Net income¥228.5M+5,9 % YoY
Free cash flow¥405.0M+29,7 % YoY
EPS—
Operating cash flow¥796.6M+27,4 % YoY
Financials
Income statement
Revenue¥2.57B
Gross profit¥1.19B
Operating income¥321.8M
Net income¥228.5M
Margins
Gross margin46.3%
Operating margin12.5%
Net margin8.9%
FCF margin15.7%
Balance sheet
Total assets¥4.28B
Total liabilities¥3.33B
Total equity¥944.6M
Cash & equivalents¥919.7M
Long-term debt¥730.6M
Cash flow
Operating cash flow¥796.6M
CapEx-¥114.2M
Free cash flow¥405.0M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue ¥2.57B, +19,9% YoY
- ▍Operating income +10,5% YoY
- ▍Net income +5,9% YoY
- ▍Free cash flow +29,7% YoY
- ▍Net margin 8.9%
ANNUALFiled 2024-03-26
FY 2024 · Full-year highlights
Revenue ¥2.15B, +31,2% YoY; Operating income +91,5% YoY.
Revenue¥2.15B+31,2 % YoY
Operating income¥291.3M+91,5 % YoY
Net income¥215.7M+109,2 % YoY
Free cash flow¥312.2M+18,5 % YoY
EPS—
Operating cash flow¥625.5M+63,8 % YoY
Financials
Income statement
Revenue¥2.15B
Gross profit¥977.1M
Operating income¥291.3M
Net income¥215.7M
Margins
Gross margin45.6%
Operating margin13.6%
Net margin10.1%
FCF margin14.6%
Balance sheet
Total assets¥3.30B
Total liabilities¥2.50B
Total equity¥801.9M
Cash & equivalents¥609.2M
Long-term debt¥563.1M
Cash flow
Operating cash flow¥625.5M
CapEx-¥159.2M
Free cash flow¥312.2M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue ¥2.15B, +31,2% YoY
- ▍Operating income +91,5% YoY
- ▍Net income +109,2% YoY
- ▍Free cash flow +18,5% YoY
- ▍Net margin 10.1%
ANNUALFiled 2023-03-29
FY 2023 · Full-year highlights
Revenue ¥1.64B, −8,2% YoY; Operating income −45,3% YoY.
Revenue¥1.64B−8,2 % YoY
Operating income¥152.1M−45,3 % YoY
Net income¥103.1M−46,7 % YoY
Free cash flow¥263.6M−24,0 % YoY
EPS—
Operating cash flow¥382.0M−43,0 % YoY
Financials
Income statement
Revenue¥1.64B
Gross profit¥717.8M
Operating income¥152.1M
Net income¥103.1M
Margins
Gross margin43.9%
Operating margin9.3%
Net margin6.3%
FCF margin16.1%
Balance sheet
Total assets¥2.50B
Total liabilities¥2.31B
Total equity¥188.7M
Cash & equivalents¥283.8M
Long-term debt¥525.5M
Cash flow
Operating cash flow¥382.0M
CapEx-¥140.8M
Free cash flow¥263.6M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue ¥1.64B, −8,2% YoY
- ▍Operating income −45,3% YoY
- ▍Net income −46,7% YoY
- ▍Free cash flow −24,0% YoY
- ▍Net margin 6.3%
Valuation FY
Market price
HK$19,75
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
—
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
1,75
Predicted surprise
+0,00
Beat probability
45 %
Analysts
7
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-19 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,75 |
| Revenue | —no estimate | —no estimate | 4,0B CNY |
| Operating income | —no estimate | —no estimate | 593,1M CNY |
Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution7 analysts
Strong buy5
Buy2
Hold0
Sell0
Strong sell0
12-month price targetHK$35,29 · Median HK$37,36
Low HK$30,00High HK$38,50
Operating income · consensus593,1M CNY
EPS surprise
−21,8 %
reported vs consensus · miss
Revenue surprise
−24,7 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
LowHK$30,00
MeanHK$35,29
MedianHK$37,36
HighHK$38,50
SpotHK$19,75
+78.7 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskUnknown
Benchmarks vs cohort
No cohort benchmark data available for this issuer yet.
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Source documents
- Beauty Farm Medical & Health Industry Inc Market data — financials · 2026-05-26
- Beauty Farm Medical & Health Industry Inc Market data — analyst estimates · 2026-05-26
Ownership & reference
Leadership
- Yang LiExecutive Chairman of the Board
Insider activity
— missing data
Short positioning
— missing data
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
2373.HKCanonical
HKEX · HKD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskUnknown
Evidence & claims
From filings & derived data— missing data
The Thread
Everything we know, in order2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-03-27 09:33 UTCEARNINGSAnnual results — FY 2026 Revenue CNY 3.00B · Net CNY 317.6M
2025-03-26 15:40 UTCEARNINGSAnnual results — FY 2025 Revenue CNY 2.57B · Net CNY 228.5M
2024-03-26 14:27 UTCEARNINGSAnnual results — FY 2024 Revenue CNY 2.15B · Net CNY 215.7M
2023-03-29 19:38 UTCEARNINGSAnnual results — FY 2023 Revenue CNY 1.64B · Net CNY 103.1M
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage